LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL(C).

    García-Carrasco, M / Mendoza-Pinto, C / Cardiel, M H / Méndez-Martínez, S / García-Villaseñor, A / Jiménez-Hernández, C / Alonso-García, N E / Briones-Rojas, R / Ramos-Álvarez, G / López-Colombo, A

    Lupus

    2012  Volume 21, Issue 11, Page(s) 1219–1224

    Abstract: The LupusQoL© questionnaire is a disease-specific health related quality of life (HRQOL) instrument for adults with systemic lupus erythematosus (SLE). The Short Form-36 (SF-36) is a generic instrument that captures the physical, psychological, and ... ...

    Abstract The LupusQoL© questionnaire is a disease-specific health related quality of life (HRQOL) instrument for adults with systemic lupus erythematosus (SLE). The Short Form-36 (SF-36) is a generic instrument that captures the physical, psychological, and social impact. We conducted a descriptive study of women aged ≥ 18 years attending our Lupus Clinic. HRQOL was assessed by applying the LupusQoL© and SF-36. Lupus activity was measured using the Mexican Systemic Lupus Erythematosus Disease Activity Index (Mex-SLEDAI) and chronic damage using the Systemic Lupus Collaborative Clinics Damage Index (SDI). Data were analyzed using descriptive statistics, the chi-square test and Pearson's product moment correlation coefficient. A total of 127 patients were included with a mean age of 40.5 ± 12.6 years. The mean disease duration was 8.2 ± 5.6 years, the mean disease activity score was 2.4 ± 3.0, and the mean SDI score 0.77 ± 1.06. The mean SF-36 score was 58.1 ± 21.1 and the mean LupusQoL© score was 69 ± 22.7. The correlation between global scores of the SF-36 and LupusQoL© was rho = 0.73 (p < 0.001). The correlation between lupus disease activity and the SF-36 and the LupusQoL© was -0.26 (p = 0.003) and -0.25 (p = 0.004), respectively. The correlation between the SDI and the SF-36 and the LupusQoL© was -0.28 (p = 0.001) and -0.38 (p < 0.0001), respectively. In conclusions: both LupusQoL© and SF-36 were useful instruments in assessing HRQOL in Mexican lupus female patients. The usefulness of the LupusQoL© should be evaluated in lupus patients with moderate to severe disease activity.
    MeSH term(s) Adult ; Chi-Square Distribution ; Cross-Sectional Studies ; Data Interpretation, Statistical ; Female ; Humans ; Lupus Erythematosus, Systemic/physiopathology ; Middle Aged ; Quality of Life ; Severity of Illness Index ; Surveys and Questionnaires
    Language English
    Publishing date 2012-10
    Publishing country England
    Document type Comparative Study ; Journal Article
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/0961203312456749
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Bone mineral density in systemic lupus erythematosus women one year after rituximab therapy.

    Mendoza Pinto, C / García Carrasco, M / Etchegaray Morales, I / Jiménez Hernández, M / Méndez Martínez, S / Jiménez Hernández, C / Briones Rojas, R / Ramos Alvarez, G / Rodríguez Gallegos, A / Montiel Jarquín, A / López Colombo, A / Cervera, R

    Lupus

    2013  Volume 22, Issue 11, Page(s) 1128–1134

    Abstract: The objective of this study was to assess the effects of rituximab on bone mineral density (BMD) in women with systemic lupus erythematosus (SLE) 1 year after treatment. Thirty active female SLE patients treated with rituximab were compared with 43 SLE ... ...

    Abstract The objective of this study was to assess the effects of rituximab on bone mineral density (BMD) in women with systemic lupus erythematosus (SLE) 1 year after treatment. Thirty active female SLE patients treated with rituximab were compared with 43 SLE women not treated with rituximab. BMD was measured using dual energy X-ray absorptiometry (DEXA) before initiating biologic therapy and after 1 year. The mean age was 38.5 ± 2.1 years; median disease duration was 7 years. In the rituximab group, after 1 year of follow-up, BMD at the femoral neck (FN) decreased from 0.980 ± 0.130 g/cm(2) to 0.809 ± 0.139 g/cm(2) (-17.4%; p=0.001). Similarly, BMD at the lumbar spine (LS) decreased from 1.062 ± 0.137 g/cm(2) to 0.893 ± 0.194 g/cm(2) (-15.8%; p=0.001). In control subjects, BMD at the FN decreased from 0.914 ± 0.193 g/cm(2) to 0.890 ± 0.135 g/cm(2) (-2.6%; p=0.001), and BMD at the LS decreased from 0.926 ± 0.128 g/cm(2) to 0.867 ± 0.139 g/cm(2) (-6.2%; p=0.09). After 1 year, SLE patients had lower BMD at both the FN and LS, but the loss was greater in postmenopausal patients who had received rituximab therapy.
    MeSH term(s) Adult ; Antibodies, Monoclonal, Murine-Derived/pharmacology ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; B-Lymphocytes/physiology ; Bone Density/drug effects ; Female ; Glucocorticoids/pharmacology ; Humans ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/metabolism ; Prospective Studies ; Rituximab ; Time Factors
    Chemical Substances Antibodies, Monoclonal, Murine-Derived ; Glucocorticoids ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2013-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/0961203313502861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Efecto in vitro de la vacuna S3Pvac contra cisticercosis en celulas mononucleares humanas.

    Díaz-Orea, María Alicia / Mijares, José Miguel / Arcega, Raúl / Gómez-Conde, Eduardo / Castellanos-Sánchez, Víctor Omar / Briones-Rojas, Rosendo / Flores-Alonso, Juan Carlos / Marín-Briones, Miguel Ángel / Santos-López, Gerardo

    Revista de neurologia

    2013  Volume 56, Issue 9, Page(s) 456–463

    Abstract: Introduction: Neurocysticercosis (NCC) is a parasitic infection caused by the establishment of Taenia solium cysticerci in the central nervous system. The larval stage of the parasite also affects the pig, which is the essential intermediate host for ... ...

    Title translation In vitro effect of the S3Pvac vaccine against cysticercosis in human mononucleate cells.
    Abstract Introduction: Neurocysticercosis (NCC) is a parasitic infection caused by the establishment of Taenia solium cysticerci in the central nervous system. The larval stage of the parasite also affects the pig, which is the essential intermediate host for transmission. For this reason, many researchers have focused on identifying protective antigens to prevent swine cysticercosis and interrupt the transmission. These include S3Pvac vaccine antigens. Vaccine is constituted by three protective synthetic peptides: KETc1, KETc12 and GK1. AIM. To evaluate the effect of the vaccine peptides KETc1, KETc12 and GK1 in mononuclear cells of patients with neuro-cysticercosis and healthy individuals.
    Subjects and methods: Comparative, prospective, transverse study. We studied the proliferation and cytokine profile induced by the three peptides in mononuclear cells from three patients with active NCC, 16 patients by calcified NCC and 16 healthy subjects.
    Results: KETc1 induces low levels of proliferation in cells from patients with active and controlled NCC, both in lymphocytes and in monocytes. KETc12 and GK-1 induce positive proliferation levels of monocytes in healthy subjects.
    Conclusions: KETc1 peptide could be used as an adjuvant in the treatment of patients with active NCC, as induced a Th2 response also GK1 peptide as stimulator of monocyte/macrophage in immunizations with other proteins.
    MeSH term(s) Adjuvants, Immunologic ; Adolescent ; Adult ; Aged ; Animals ; Antigens, Helminth/analysis ; Antigens, Helminth/immunology ; Calcinosis/blood ; Calcinosis/immunology ; Cell Division/drug effects ; Cells, Cultured ; Cross-Sectional Studies ; Cysticercus/immunology ; Cysticercus/ultrastructure ; Drug Evaluation, Preclinical ; Female ; Fluorescent Antibody Technique, Indirect ; Humans ; In Vitro Techniques ; Interferon-gamma/secretion ; Interleukins/secretion ; Lymphocytes/drug effects ; Lymphocytes/secretion ; Male ; Middle Aged ; Monocytes/drug effects ; Monocytes/secretion ; Neurocysticercosis/blood ; Neurocysticercosis/immunology ; Peptide Fragments/chemical synthesis ; Peptide Fragments/immunology ; Prospective Studies ; Vaccines, Subunit/immunology ; Vaccines, Subunit/pharmacology ; Young Adult
    Chemical Substances Adjuvants, Immunologic ; Antigens, Helminth ; Interleukins ; Peptide Fragments ; Vaccines, Subunit ; Interferon-gamma (82115-62-6)
    Language Spanish
    Publishing date 2013-05-01
    Publishing country Spain
    Document type Comparative Study ; English Abstract ; Journal Article
    ZDB-ID 1468278-3
    ISSN 1576-6578 ; 0210-0010
    ISSN (online) 1576-6578
    ISSN 0210-0010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top